We offer a targeted, effective and safer
CANCER
TREATMENT
TREATMENT
Ambrego's individualized treatment induces cell-cycle arrest only on cancerous cells, allowing the far safer Ambrego treatment to completely replace the conventional chemotherapy. Also, Ambrego's treatment actively destroys cancerous cells. Given as a supplement to conventional chemotherapy, it can turn a palliative chemotherapy treatment into an effective treatment which cures the patient. Suitable for both humans and animals.
We offer a targeted, effective and safer
CANCER
TREATMENT
Ambrego's individualized treatment induces cell-cycle arrest targeted only on cancerous cells, allowing the far safer Ambrego treatment to completely replace the conventional chemotherapy. Also, Ambrego's treatment actively destroys cancerous cells. Given as a supplement to conventional chemotherapy, it can turn a palliative chemotherapy treatment into an effective treatment which cures the patient. Suitable for both humans and animals.
How The Treatment Improves
on the prior state of the art
Chemotherapy not only acts on cancerous cells, but also other fast-dividing cells such as hair follicles and bone marrow. Many patients can accept the massive side effects, however for others the resulting side effects are straight-out dangerous (children, persons with pre-existing conditions). Due to the targeting, these side effects do not exist with the Ambrego therapy.
> Safer but just as effective replacement to chemotherapy for high risk patients
In contrast to chemotherapy which only induces cell-cycle arrest, one component of the Ambrego therapy actively destroys cancerous cells (induces apoptosis). Given as a supplement to conventional chemotherapy, it can turn a palliative chemotherapy treatment into an effective treatment which cures the patient.
> Effective cure for many situations where conventional chemotherapy alone no longer cures the patient
The individualized drugs actively target the cells by recognizing the DNA mutations themselves. No prediction or profiling, which per definition is inaccurate, as with individualized immunotherapy, no interpretation of the DNA mutations.
> Ultra targeted, resulting in higher efficacy and fewer side effects.
Prior treatment, the effectiveness of the individualized drugs is tested in-vitro with the patient's cell samples, then in patient's body with MRI marker drugs which use the same targeting mechanism as the active drugs.
> No time is lost with ineffective treatments.
If the tests prior treatment show that the individualized drugs are not effective due to being immune to the proteins expressed or genes silenced, they can be easily changed to target other signalling pathways in the cell.
> Thus a high chance for success even if the tumor does not respond to other treatments.
Chemotherapy not only acts on cancerous cells, but also other fast-dividing cells such as hair follicles and bone marrow. Many patients can accept the resulting side effects, however for others the resulting side effects can be straight-out dangerous (children, persons with pre-existing conditions). Due to the targeting, these side effects do not exist with the Ambrego therapy.
> Therefore, far fewer dangerous side effects.
In contrast to chemotherapy, Ambrego therapy does not have to take into account healthy cells, which are also attacked. Thus, the individualized drugs can be fine tuned for far effectiveness towards the cancerous cells.
> Therefore, much higher efficacy.
The individualized drugs actively target the cells by recognizing the DNA mutations themselves. No prediction or profiling, which per definition is inaccurate, as with individualized immunotherapy, no interpretation of the DNA mutations.
> Again, higher efficacy and fewer side effects.
Prior treatment, the effectiveness of the individualized drugs is tested in-vitro with the patient's cell samples, then in patient's body with MRI marker drugs which use the same targeting mechanism as the active drugs.
> No time is lost with ineffective treatments.
If the tests prior treatment show that the individualized drugs are not effective due to being immune to the proteins expressed or genes silenced, they can be easily changed to target other signalling pathways in the cell.
> Thus a high chance for success even if the tumor does not respond to other treatments.
The Treatment Process
Manufacturing of the drugs (4-6 weeks)
01
The oncologist does a biopsy of the tumor(s), and also harvests samples of healthy cells from the patients.
02
The samples are shipped to the Ambrego Labs in Düsseldorf, Germany.
03
Using whole genome sequencing techniques, Ambrego Labs detects DNA mutations which best seperates the healthy from the cancer cells.
04
Ambrego Labs produces 4 drugs which have an effect only on cells with the DNA mutations (cancerous cells):
one to mark cells with eGFP (visible in microscope)
one to mark cells with MRI contrast substance
one to induce cell-cycle-arrest (meaning: inhibits cell growth)
one to initiate apoptosis (meaning: destroys cells)
one to mark cells with eGFP (visible in microscope)
one to mark cells with MRI contrast substance
one to induce cell-cycle-arrest (meaning: inhibits cell growth)
one to initiate apoptosis (meaning: destroys cells)
05
Ambrego Labs verifies with the drug 1 in-vitro (meaning: in a petri dish) that the mutations split the two cell samples of the patient (healthy and cancerous cells) correctly. If not, drugs targeting other mutations are produced.
06
Ambrego Labs verifies with drug 3 and drug 4 in-vitro that the cancerous cells respond to the active ingredients expressed on cancer cell detection. If not, drugs with alternative active ingredient targeting other cell pathways are produced.
07
Ambrego Labs ships drugs 2, 3 and 4 to the oncologist.
08
Use drug 2 and a subsequent full body MRI scan, the oncologist checks whether the cancerous cells are precisly targeted.
The actual treatment
The goal of the Ambrego treatment is to cure cancer in a controlled manner. There are no treatment cycles in which a combination of drugs is administered and the body then has to recover for a longer time, as with conventional chemotherapy.
As part of the Ambrego treatment, one drug is used to put the cancer cells into constant cell cycle arrest, meaning the cancer cells can no longer divide and therefore grow. With another drug, the cancer cells are destroyed, but, as there is no race to combat cancer growth, only at a pace that does not overwhelm the patient.
The patient has a good chance of living a normal life during the treatment and of being cured at the end of the treatment.
The In-Cell Technology
The treatment is based on the Ambrego in-cell technology for rapid protein expression or gene inhibition on DNA sequence detection. A quick simplified overview for scientists without the details:
01
All components of the Ambrego technology are delivered into the cells, in a way that they do not result in an immune response.
Parts of the components are two highly accurate, disabled CRISPR-Cas9 (dCas9) proteins, both linked to a part of a split RNA-dependent RNA polymerase protein (RdRp) which, as long as the dCas9 protein is not bound to DNA, are in addition bound the the dCas9 protein in a way that the RdRp cannot function.
Another part of the components is the negative-stranded RNA which encodes a protein to express in the cancerous cells.
02
The two dCas9 proteins bind on the DNA at the targeted mutation, both next to each other. This is only successful if the cell includes the targeted mutation which only exists in the cancerous cells.
03
On binding, the dCas9 proteins no longer bind the RdRp parts, which, while still being linked to the dCas9 proteins, can now bind to each other, resulting into an active RdRp protein.
04
The RNA encoding the protein to be expressed gets transcribed again and again into mRNA by the RdRp. The mRNAs are then translated into the proteins which shall be expressed in the cancerous cells.
05
These proteins can then mark the cell, signal cell apopostis or take other action.
If a gene shall be inhibited, the protein is another dCas9 protein incompatible to the guide RNAs of the first two dCas9 proteins. This third dCas9 protein together with a third guide RNA which is also part of the components inhibit the gene via the CRISPRi mechanism.
The first proof of concept was based only on one protein: A Cas9 protein fused with a full RdRp protein, which bind together as long as they do not detect the DNA mutation and with this keep the RdRp inactive, but no longer bind and only connect via linker as soon as they detect the DNA mutation and thus enable the RdRp.
Many often asked questions about the efficacy and safety of the Ambrego technology are answered in our Questions & Answers section.
